omalizumab

JDD April 2024 Issue Highlights
215362153621536Skin treatmentIntroducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen …
Skin treatment
Biologics and Immunomodulators for Immunobullous Diseases
180921809218092Immunobullous DiseasesAt ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here. Pemphigus The pemphigus group of diseases is characterized by intraepidermal auto …
Immunobullous Diseases
Omalizumab Therapeutic Cheat Sheet
168861688616886OmalizumabChronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Omalizumab